IL2 and neoplasm: Since systemic exposure to high-dose IL2 often results in grade 3 or 4 adverse events in patients [43], we tested the combination of T cells with a tumor-targeted IL2, as a strategy to reduce exposure to healthy organs and focus IL2 activity at the site of disease.